• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Action Pharma

edit

Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company’s product pipeline includes AP214, a modified ÐMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark.

Recent Milestones

edit

• 
  Action Pharma received $6.3M in Series C funding. (7/16/10)
  Posted 7/16/10 at 5:59pm via onbiovc.com
• 
  Action Pharma added Soren Nielsen as COO.
  Posted 7/16/10 at 5:59pm
• 
  Action Pharma added Ingelise Saunders as CEO.
  Posted 7/16/10 at 5:59pm
• 
  Action Pharma added Thomas Jonassen as CSO.
  Posted 7/16/10 at 5:59pm

Videos

Screenshots

edit

Sources

1. Action Pharma, A/S: Series C $6.3M (onbiovc.com) [edit]